American Society of Retina Specialists

Bevacizumab Step-Therapy Efficacious on nAMD Trial

July 30, 2020

Article

There has been controversy over the efficacy and safety of step-therapy for neovascular age-related macular degeneration.

Ongoing Trial Assesses New Anti-VEGF Gene Therapy Injection for nAMD

July 29, 2020

Article

No serious adverse events reported through 24 weeks of a 52 week trial.

How Ophthalmology Has Evolved During COVID-19

July 29, 2020

Video

A perspective on what's moved virtually, and what hasn't, since the pandemic began in March.

Dexamethasone Implant and Anti-VEGF Therapy Effective for NAMD

July 29, 2020

Article

Combining the dexamethasone implant with anti-VEGF treatment can restore foveal anatomy in eyes resistant to anti-VEGF injection.

Early Combination Therapy Results Show Efficacy for Diabetic Macular Edema

July 28, 2020

Article

In a phase 1b study presented virtually during ASRS 2020, investigators found a reduction in central subfield thickness after 12 weeks of OPT-302 combined with aflibercept injections.

Study Warrants Screening for Both Eyes in DME Patients

July 28, 2020

Article

An interview with a Cleveland Clinic investigator on adjusting macular edema screening methods.

Researchers Take an Overview Approach to nAMD Treatment Burden and Vision Analysis

July 28, 2020

Article

The mean number of injections in the studies over 12 months was 9.36 ± 2.66, with a mean change in ETDRS letters was 7.86 ± 1.37.

Anti-VEGF Injections Associated with Cognitive Impairment in AMD Patients

July 28, 2020

Article

Interim findings from a cross-sectional study shows a correlation between worse cognitive scoring and a greater rate of intravitreal injections.

Telescreening Programs Could Help Identify the Rates of Retinal Pathology

July 28, 2020

Article

A total of 115 of 200 examined eyes had some form of diabetic retinopathy in data presented at the ASRS 2020 virtual meeting.

Strategies Needed to Improve Visual Acuity for Diabetic Macular Edema

July 28, 2020

Article

Patients demonstrate visual gains from baseline but mean visual acuity worsens between 2 and 5 years.

x